October 3, 2022

Medical Trend

Medical News and Medical Resources

AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy

AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy



 

AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy.

On March 1, 2022, Alexion, a rare disease-focused company under AstraZeneca, announced the completion of an exclusive global collaboration and license agreement with Neurimmune for NI006.

NI006 is an investigational humanized monoclonal antibody currently under development in Phase 1b clinical trials for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a systemic, progressive and fatal disease that can lead to progressive heart failure and death within four years of diagnosis.

 

AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy

 

Globally, there are an estimated 300,000 to 500,000 patients with ATTR-CM. Due to aging or genetic mutation, the TTR amyloid protein is misfolded and deposited in the myocardium as amyloid fibrils, thereby impairing the normal function of the corresponding organs and tissues.

The increase in TTR protein fibrils leads to more tissue damage and disease progression, resulting in reduced quality of life and eventual death.

 

NI006 specifically targets misfolded transthyretin, which is expected to treat patients with advanced ATTR-CM by clearing amyloid fibril deposits in the heart, targeting the pathological cause of ATTR-CM. Preclinical models demonstrate that NI006 induces clearance of pathological ATTR.

 

Under the terms of the agreement, Alexion receives an exclusive worldwide license to develop, manufacture and commercialize NI006.

NI006 adds a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis. Alexion pays Neurimmune $30 million upfront.

Neurimmune is also eligible to receive up to $730 million in development, regulatory and commercial milestone payments, as well as royalties on net sales of future approved drugs.

Neurimmune will continue to be responsible for completing Phase 1b clinical trials of the current drug, and Alexion will pay certain trial fees and will be responsible for further future clinical development, manufacturing and commercialization activities.

 

 

 

 

 

References:

[1] AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006. Retrieved March 1, 2022, from https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/astrazeneca-and-neurimmune-close-deal-for-ni006.html

AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy

(source:internet, reference only)


Disclaimer of medicaltrend.org